Peer Review History

Original SubmissionNovember 12, 2024
Decision Letter - Vittorio Sambri, Editor

PONE-D-24-51452Risk Management in POCT Blood Glucose Monitoring: FMEA Approach Aligned with ISO 15189:2022PLOS ONE

Dear Dr. Xia,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 20 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Vittorio Sambri, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your Data Availability Statement is currently as follows: 

“All relevant data are within the manuscript and its Supporting Information files.”

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

Additional Editor Comments:

In detail, your manuscript has been evaluated by two experts in the field of the use of POCT and bio

th found your study interesting. I fully agree with their suggestions and I encourage you to take into consideration their suggestion in oprder to improve the quality and value of your paper.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The use of POCT systems in laboratory medicine is increasingly widespread.

Having correct and rapid laboratory data brings a great advantage to the clinician. The manuscript analyzes the critical issues of these systems and provides useful information. It's a good article.

Reviewer #2: General: Well written

Specific:

Line 29: ”..in clinical settings….” – however, the study was not conducted in a clinical setting - but in a clinical laboratory setting (line 111), which can only simulated a “real” clinical setting. So, the study does not reflect “real life” POCT. This should be clarified and discussed. Clearly, a risk assessment conducted by certified laboratory staff I a clinical laboratory setting is different from a risk assessment in a real clinical setting (e.g., in an ER).

Line 141 / Table1: Probability – the differences should be described – are the different probabilities based on actual frequencies (e.g., 10-6, etc) or purely descriptive? Severity: The description of the five different severity levels should be included – e.g., Catastrophic: Is the definition of this severity “Death or life-threatening injury or illness” – or?

Line 154-159: “Inadequate” and “insufficient” appears several places. What is the difference?

Line 161 / Table 2: Are the described probabilities based on actual observations / data – or estimates?

Line 161 / Table 2: You mention “validation” on several occasions. Do you mean “verification”?

Line 161 / Table 2 / Analytical-Data Management: The implemented risk control measure is “Patient information and test results are entered manually and verified”. Why not use scanning of barcodes and integration with LIS? This will reduce / remove human errors?

Line 181 / Table 3 / 2. Insufficient personnel training: The implemented risk control measure is “IT driven” for Peking and “Manual tracking” for Wuhan. Why different? Why not implement IT driven in Wuhan also?

Line 181 / Table 3 / 5. Data management: The implemented risk control measure is “automated” for Peking and “Manual verification” for Wuhan. Why different? Why not implement automated in Wuhan also?

Line 193: “…but also enhanced the overall reliability of POCT….”: How do you support this claim? Data? Subjective evaluation?

Line 200-206: If manual data entry was a risk at Peking (and had to be mitigated), why was it not considered a risk at Wuhan?

Line 243-251: You sate “….highlights the efficiency of FMEA…..” and “….have significantly improved….”. Where is the data to support these claims? “Significantly” is a bold claims that requires data

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes:  Torello Monica

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

In response to the reviewers’ feedback:

Methodological clarity: We have revised the description of the study setting to clarify that the research was conducted in a simulated clinical laboratory setting. Additionally, we included a discussion on the limitations of using such a setting compared to real-life clinical environments, such as emergency rooms.

Risk assessment details: The descriptions of probability levels and severity classifications in Table 1 have been expanded. Clear definitions for each level (e.g., “Catastrophic” meaning death or life-threatening injury) are now provided to enhance the transparency and interpretability of the risk assessment.

Terminology precision: We have clarified the distinction between “validation” and “verification” in accordance with ISO 15189:2022 standards, and have updated the manuscript by replacing the relevant instances of “validation” with “verification,” ensuring consistency and accuracy throughout the manuscript.

Data management improvements: Due to limitations in resources and infrastructure availability at Wuhan Third Hospital, manual verification remains the current practice. The risk management team have proposed a gradual implementation of automated data management systems in resource-limited settings at Wuhan Third Hospital.

Subjective evaluations: Statements regarding improvements (e.g., "significantly improved" has been replaced with “noticeably improved” in the results section) have been revised to reflect that they were based on expert team feedback. We have emphasized the need for future studies to validate these findings with quantitative data.

FMEA limitations: We have elaborated on the limitations of the FMEA method, including its reliance on expert consensus and the lack of detailed quantitative data. This discussion has been added to the "Discussion" sections.

Attachments
Attachment
Submitted filename: Point by point responses to the reviewers(1).doc
Decision Letter - Vittorio Sambri, Editor

Risk Management in POCT Blood Glucose Monitoring: FMEA Approach Aligned with ISO 15189:2022

PONE-D-24-51452R1

Dear Dr. Xia,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Vittorio Sambri, M.D., Ph.D.

Academic Editor

PLOS ONE

Formally Accepted
Acceptance Letter - Vittorio Sambri, Editor

PONE-D-24-51452R1

PLOS ONE

Dear Dr. Xia,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Vittorio Sambri

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .